Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: August 11, 2022

TAZVERIK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Tazverik, and when can generic versions of Tazverik launch?

Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this drug.

This drug has three hundred and twenty-four patent family members in thirty-eight countries.

The generic ingredient in TAZVERIK is tazemetostat hydrobromide. Additional details are available on the tazemetostat hydrobromide profile page.

DrugPatentWatch® Generic Entry Outlook for Tazverik

Tazverik will be eligible for patent challenges on January 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for TAZVERIK
International Patents:324
US Patents:23
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 64
Clinical Trials: 9
Patent Applications: 365
Drug Prices: Drug price information for TAZVERIK
What excipients (inactive ingredients) are in TAZVERIK?TAZVERIK excipients list
DailyMed Link:TAZVERIK at DailyMed
Drug patent expirations by year for TAZVERIK
Drug Prices for TAZVERIK

See drug prices for TAZVERIK

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAZVERIK

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Susan ChiPhase 1/Phase 2
Dr. Victor H.F. LeePhase 2
Bristol-Myers SquibbPhase 1/Phase 2

See all TAZVERIK clinical trials

US Patents and Regulatory Information for TAZVERIK

TAZVERIK is protected by thirty-six US patents and five FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAZVERIK

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhibitors of human EZH2 and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Inhibitors of human EZH2 and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Methods of treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

FDA Regulatory Exclusivity protecting TAZVERIK

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
Exclusivity Expiration: See Plans and Pricing

TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: See Plans and Pricing

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: See Plans and Pricing

INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TAZVERIK

When does loss-of-exclusivity occur for TAZVERIK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15350108
Estimated Expiration: See Plans and Pricing

Patent: 21204706
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2017010166
Estimated Expiration: See Plans and Pricing

Canada

Patent: 67664
Estimated Expiration: See Plans and Pricing

China

Patent: 7249591
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1791095
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 20916
Estimated Expiration: See Plans and Pricing

Israel

Patent: 2182
Estimated Expiration: See Plans and Pricing

Japan

Patent: 29684
Estimated Expiration: See Plans and Pricing

Patent: 17537899
Estimated Expiration: See Plans and Pricing

Patent: 21073241
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 17006089
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201703806X
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2338802
Estimated Expiration: See Plans and Pricing

Patent: 170103768
Estimated Expiration: See Plans and Pricing

Patent: 210156840
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAZVERIK around the world.

Country Patent Number Title Estimated Expiration
New Zealand 706738 Substituted benzene compounds See Plans and Pricing
Russian Federation 2662436 СОДЕРЖАЩИЕ ЗАМЕСТИТЕЛИ БЕНЗОЛЬНЫЕ СОЕДИНЕНИЯ (SUBSTITUTED BENZENE COMPOUNDS) See Plans and Pricing
Russian Federation 2015118145 ЗАМЕЩЕННЫЕ БЕНЗОЛЬНЫЕ СОЕДИНЕНИЯ See Plans and Pricing
South Korea 20190121386 아릴- 또는 헤테로아릴-치환된 벤젠 화합물 (- - ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS) See Plans and Pricing
Japan 5933686 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
McKinsey
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.